Synthetic Studies on the Starfish Alkaloid Imbricatine. Construction of an *ent*-Imbricatine Framework

Masashi Онва,* Masaaki Iмаsно, and Tozo Fuлi

Faculty of Pharmaceutical Sciences, Kanazawa University, Takara-machi, Kanazawa 920–0934, Japan. Received August 26, 1998; accepted October 11, 1998

A chiral synthetic route to the amino esters 5 and 6, which contain the fundamental framework of *ent*-imbricatine (*ent*-3), has been developed as a prelude to the total synthesis of the starfish alkaloid imbricatine (3). The route started from the sulfur-containing L-phenylalanine derivative 7 and proceeded through key steps such as cyclization of the amide 8 without racemization, reduction to the 1,3-*cis*-tetrahydroisoquinoline 9, and introduction of a chiral α -amino acid moiety into the chloride 18 by the "bis-lactim ether" method.

Key words imbricatine; benzyltetrahydroisoquinoline alkaloid; arylthiohistidine synthesis; Bischler–Napieralski cyclization; X-ray analysis; bis-lactim ether

In 1986, Pathirana and Andersen reported the isolation of an unusual benzyltetrahydroisoquinoline alkaloid, named imbricatine, from the starfish Dermasterias imbricata and proposed the gross structure 1 on the basis of spectroscopic analysis and chemical degradation.¹⁾ Imbricatine is unique in that it is extremely effective at causing the detachment and swimming response in the sea anemone Stomphia coccinea at very low concentrations.^{1,2)} This compound is the first example of a benzyltetrahydroisoquinoline alkaloid obtained from a nonplant source and possesses some structural features, such as the carboxy group at the 3-position, the 6,8dihydroxylation pattern, and the thioether linkage to the 3methylhistidine moiety, not previously encountered in this family of alkaloids, and it displays significant activity in antineoplastic assays.^{1,3)} In view of these striking characteristics, we planned the chiral synthesis of the target structure 2 envisioned as a probable candidate for imbricatine on the assumption that both α -amino acid portions of 1 would be biogenetically derived from the usual L-amino acids. After the present study was undertaken, however, Andersen and coworkers deduced the absolute configurations of the three stereogenic centers of imbricatine to be those in 3 (1R,3R,7'S).³⁾ In this full account, we describe the synthesis of the amino ester 5 containing the entire framework of entimbricatine (ent-3), together with the 7'-epimer 6, as a prelude to the total synthesis of imbricatine (3). On the basis of these syntheses, we have recently accomplished the chiral synthesis of tri-O-methylimbricatine (4), the tri-O-methyl derivative of 3, and unequivocally confirmed the structure and absolute stereochemistry proposed for imbricatine.⁴⁾

In connection with our ongoing synthetic studies of imbri-

phenylalanine derivative 7 (95% ee) containing at the 2-position a thiol group protected with the 4-methoxybenzyl group.⁶⁾ The initial step of the present work was coupling of 7 with 4-methoxyphenylacetyl chloride, which proceeded smoothly under Schotten-Baumann conditions to provide the amide 8 in 98% yield. The optically pure 8, obtained by recrystallization of the crude amide, was then subjected to Bischler-Napieralski cyclization using POCl₃ in toluene at 80 °C for 7 h followed by NaBH₄ reduction in MeOH at $-78 \,^{\circ}\text{C}^{.7}$ However, the 1.3-*cis* isomer 9 that resulted as a sole product in 83% overall yield was shown⁸⁾ to be of 85% enantiomeric purity. Kametani et al. reported that treatment of N-acetyl-L-3,4-dimethoxyphenylalanine methyl ester with POCl₃ in CH₃CN at room temperature for 2 h produced the corresponding 3,4-dihydroisoquinoline without accompanying racemization.⁹⁾ Although cyclization of 8 was very sluggish under the same conditions, it proceeded moderately by heating at 60 °C,¹⁰ giving 9 of 96% ee⁸ in 78% overall yield after NaBH₄ reduction. Optically pure 9 was readily obtained by recrystallization from MeOH. The ester group of 9 was then reduced with LiAlH₄ to afford 10 in 84% yield, since partial or complete epimerization at the 3-position was assumed to be a potential problem at later stages.

catine,⁵⁾ we have already reported the synthesis of the L-

Alternatively, conversion of **8** into **10** was achieved without partial racemization by exploiting a route *via* cyclization of an equivalent amide bearing a protected hydroxymethyl group instead of the methoxycarbonyl group, such as **12**. Thus, the amide ester **8** was first reduced with LiBH₄ in 99% yield, and the resulting amide alcohol **11** was then protected with an acetyl group by treatment with acetic anhydride and



* To whom correspondence should be addressed.

© 1999 Pharmaceutical Society of Japan



Reagents and Conditions: (a) 4-methoxyphenylacetyl chloride, Na₂CO₃, H₂O-benzene, 8-10 °C, 30 min; (b) 1) POCl₃, toluene, 80 °C, 7 h or POCl₃, CH₃CN, 60 °C, 10 h; 2) NaBH₄, MeOH, -78 °C, 1 h; (c) LiAlH₄, THF, rt, 1.5 h; (d) LiBH₄, THF, rt, 1.5 h; (e) Ac₂O, pyridine, rt, 1.5 h; (f) 1) POCl₃, toluene, reflux, 1.5 h; (2) NaBH₄, MeOH, -78 °C, 1 h; (g) K₂CO₃, aqueous MeOH, rt, 1 h; (h) (EtO)₂CO, NaOEt, EtOH, reflux, 6 h; (i) (CF₃CO₂)₂Hg, anisole, EtOH, rt, 14.5 h, then NaBH₄, 0 °C, 15 min



Reagents and Conditions: (a) 23, NaH, DMF, 100 °C, 3 h; (b) NaBH₄, MeOH, rt, 1 h; (c) SOCl₂, rt, 1 h; (d) (*R*)-24, THF, -78 °C, 2 h, -50 °C, 20 h; (e) (*S*)-24, THF, -78 °C, 2 h, -50 °C, 20 h

Chart 2

pyridine to furnish **12** in 93% yield. Bischler–Napieralski cyclization of **12** with POCl₃ in boiling toluene for 1.5 h, followed by NaBH₄ reduction, provided **13** in 88% overall yield. Finally, deacetylation of **13** with K_2CO_3 in aqueous MeOH gave the optically pure **10** in 86% yield. After the OH and NH groups of **10** were protected in the form of the oxazolidinone **14** (91% yield) by treatment with diethyl carbonate and NaOEt in EtOH, conversion into the thiol **15** was examined. Among several methods reported in the literature¹¹ for de-

protection of the S-(4-methoxybenzyl) group, Fujino's procedure¹²⁾ with minor modification was found to be most effective. Thus, treatment of **14** with $(CF_3CO_2)_2Hg$ in EtOH containing anisole and subsequent NaBH₄ reduction of the resulting mercaptide provided **15** in 90% yield.

Having developed a chiral synthesis of the benzyltetrahydroisoquinoline moiety possessing the thiol group required for construction of *ent*-imbricatine, we set out to explore the application to **15** of our previously established synthetic

Protons ^{b)}	Chemical shift (ppm)			
	14	15	16	17
C(1)-H's	3.50 (1H, dd)	3.62 (1H, dd)	3.63 (1H, dd)	3.68 (1H, dd)
	[<i>J</i> =11, 8 Hz]	[<i>J</i> =11, 7.5 Hz]	[<i>J</i> =11, 7.5 Hz]	[J=10.5, 7 Hz]
	4.10 (1H, dd)	4.33 (1H, dd)	4.33 (1H, dd)	4.38 (1H, dd)
С(5)-Н	[J=8 Hz each]	[J=7.5 Hz each]	[J=7.5 Hz each]	[J=7 Hz each]
	5.28 (1H, dd)	5.34 (1H, dd)	5.33 (1H, dd)	5.30 (1H, dd)
	[J=5, 2 Hz]	[J=5, 2 Hz]	[J=5, 2 Hz]	[J=5, 2.5 Hz]
С(10)-Н _{<i>α</i>}	2.87 (1H, dd)	2.72 (1H, dd)	3.42 (1H, dd)	3.87 (1H, dd)
	[<i>J</i> =14.5, 3 Hz]	[J=14.5, 3 Hz]	[J=15, 3 Hz]	[<i>J</i> =15, 2.5 Hz]
С(10)-Н _β	0.63 (1H, dd)	0.78 (1H, dd)	0.87 (1H, dd)	0.95 (1H, dd)
	[J=14.5, 11.5 Hz]	[<i>J</i> =14.5, 11 Hz]	[J=15, 11.5 Hz]	[<i>J</i> =15, 11 Hz]
С(10а)-Н	3.12 (1H, dddd)	3.71 (1H, dddd)	3.74 (1H, dddd)	3.74 (1H, dddd)
	[J=11.5, 11, 8, 3 Hz]	[J=11, 11, 7.5, 3 Hz]	[J=11.5, 11, 7.5, 3 Hz]	[J=11, 10.5, 7, 2.5 Hz]
C(5)-CH ₂	2.78 (1H, dd)	2.78 (1H, dd)	2.80 (1H, dd)	2.77 (1H, dd)
	[J=13.5, 2 Hz]	[J=13.5, 2 Hz]	[J=13.5, 2 Hz]	[J=13.5, 2.5 Hz]
	3.54 (1H, dd)	3.64 (1H, dd)	3.65 (1H, dd)	3.63 (1H, dd)
	[J=13.5, 5 Hz]	[J=13.5, 5 Hz]	[J=13.5, 5 Hz]	[J=13.5, 5 Hz]
OMe ^{c)}	3.68 (3H, s) 3.74 (3H, s) 3.90 (3H, s) 3.97 (3H, s)	3.74 (3H, s) 3.90 (3H, s) 3.96 (3H, s)	3.74 (3H, s) 3.88 (3H, s) 3.90 (3H, s) 3.92 (3H, s)	3.66 (3H, s) 3.75 (3H, s) 3.88 (3H, s) 3.97 (3H, s)
C(7)-H	6.46 (1H, s)	6.49 (1H, s)	6.49 (1H, s)	6.46 (1H, s)
C(3')-H and	6.46 (2H, d)	6.46 (2H, d)	6.47 (2H, d)	6.42 (2H, d)
C(5')-H	[J=8.5 Hz]	[J=8.5 Hz]	[J=9 Hz]	[J=8.5 Hz]
C(2')-H and	6.60 (2H, d)	6.65 (2H, d)	6.54 (2H, d)	6.49 (2H, d)
C(6')-H	[<i>J</i> =8.5 Hz]	[<i>J</i> =8.5 Hz]	[<i>J</i> =9 Hz]	[<i>J</i> = 8.5 Hz]
Others	3.60 (1H, d) [J=12.5 Hz] 3.71 (1H, d) [J=12.5 Hz] 6.69 (2H, d) [J=8.5 Hz] 6.87 (2H, d) [J=8.5 Hz]	3.74 (1H, s)	7.39 (1H, s) 9.98 (1H, s)	2.13 (1H, t) [J=6 Hz] 4.74 (1H, dd) [J=13, 6 Hz] 4.78 (1H, dd) [J=13, 6 Hz] 7.25 (1H, s)

Table 1. ¹H-NMR Spectral Data for the Oxazolidinones **14**–17^{*a*} in CDCl₃

a) See formula 14 in Chart 1 for the numbering system. b) For convenience, each aromatic carbon in the 4-methoxybenzyl group substituted at the 5-position is indicated by a primed number. c) Data for 16 and 17 include N-Me signals.

route to 5-arylthio-3-methyl-L-histidines.⁵⁾ Coupling of **15** with the bromo aldehyde **23**⁵⁾ was carried out in DMF in the presence of NaH at 100 °C for 3 h, affording the thioether **16** (82% yield), which was then converted into the alcohol **17** (mp 250.5—251.5 °C) in 82% yield by NaBH₄ reduction.

During these studies, it was noted that one of the C(10)protons of the oxazolidinone 14 was found to resonate at extraordinarily high field (δ 0.63), as shown in Table 1, compared to the corresponding proton (δ 1.82) of the amino alcohol 10. Similarly, large upfield shifts were observed for the C(10)-H_B signals of the other oxazolidinones 15–17. In order to ascertain the reason for such upfield shifts of the proton signals in question, as well as to confirm the stereochemistry of the oxazolidinones, the alcohol 17 was subjected to a single crystal X-ray analysis. The derived molecular structure (Fig. 1) established the 5,10a-cis stereochemistry for the tetrahydroxazolo[3,4-b]isoquinolin-3(3H)-one moiety of 17. Furthermore, it can be seen from Fig. 1 that the plane of the 4-methoxyphenyl ring system lies over the C(10)-H_{β}, probably owing to steric repulsion by the carbonyl group at the 3-position and the methoxy group at the 6-position, causing its proton signal to appear at higher field.

With the stereochemistry of **17** confirmed, we next turned our attention to the completion of the histidine moiety by means of the "bis-lactim ether" method of Schöllkopf.¹³⁾



Fig. 1. ORTEP Representation of the Crystal Structure of 17

Chlorination of **17** with SOCl₂ at room temperature for 1 h and subsequent coupling of the resulting chloride **18** with the organolithium reagent (*R*)-**24**, generated *in situ* by regio-selective metalation of (2R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine with LDA in THF–hexane at -78 °C,



Chart 3

afforded an inseparable 1.4:1 diastereoisomeric mixture¹⁴) of **19** and **20**¹⁵ in 56% yield from **17**. Similarly, treatment of **18** with the enantiomeric organolithium reagent (*S*)-**24** also gave a mixture of two diastereoisomers, but the mixture could be separated by flash chromatography¹⁶ to provide **21** and **22** in 55% and 31% yields, respectively, from **17**. The stereochemistries of the newly formed stereogenic centers in **21** and **22** were determined on the basis of comparison of the chemical shifts of their C(2")-protons. In CDCl₃, the C(2")proton (δ 3.78) of **21** resonated at higher field than the corresponding proton (δ 3.93) of **22**. This permitted us to assign **21** and **22** to the *trans* and *cis* structures, respectively, since the C(2)-proton signals of the *trans* isomers **25a**, **b** are known to appear at 0.12—0.13 ppm upfield of those of the *cis* isomers **26a**, **b**, because of the shielding effect induced by the imidazole ring.^{5b)} The observed low diastereoselectivity in the formation of **19** and **20** (1.4:1) as well as **21** and **22** (1.8:1), compared with the cases of **25a**, **b** and **26a**, **b** (**25a**: **26a**=14:1; **25b**: **26b**=17:1) in a similar alkylation of (*R*)-**24** generated from the (2*R*)-dihydropyrazine and BuLi,⁵⁾ was an entirely unexpected result, although different bases were used for preparation of the organolithium reagents (*R*)-**24** and (*S*)-**24**.

Finally, the *trans* and *cis* bis-lactim ethers **21** and **22** were separately hydrolyzed with 0.25 N aqueous HCl in MeOH to furnish the desired amino esters **5** and **6** in 71% and 75% yields, respectively. In order to confirm the structure and absolute configuration of **5**, desulfurization was effected with Raney Ni in boiling H₂O–MeOH (1:4, v/v), giving the oxazolidinone **27** in 83% yield, together with the amino acid **28** obtained in 46% yield after hydrolysis with 6 N aqueous HCl. The latter amino acid was identified as 3-methyl-D-histidine by comparison of its ¹H-NMR spectrum and optical rotation with those of commercially available 3-methyl-L-histidine.

In conclusion, the present work has developed a synthetic route to the amino esters **5** and **6** containing the fundamental framework of *ent*-imbricatine (*ent*-**3**). Furthermore, this effort led to our successful chiral synthesis of tri-O-methylimbricatine (**4**), which confirmed the structure and absolute configuration assigned to the starfish alkaloid imbricatine (**3**).⁴

Experimental

General Notes All melting points were determined on a Büchi model 530 capillary melting point apparatus and are corrected. TLC and preparative TLC were run on Merck 0.25-mm and 0.50-mm precoated silica gel 60 F₂₅₄ plates, respectively. Flash chromatography¹⁶⁾ was carried out by using Merck silica gel 60 (No. 9385). Unless otherwise noted, the organic solutions obtained after extraction were dried over anhydrous Na2SO4 and concentrated under reduced pressure. Spectra reported herein were recorded on either a Hitachi M-80 or a JEOL JMS-SX102A mass spectrometer, either a JASCO A-202 or a Shimadzu FTIR-8100 IR spectrophotometer, and either a JEOL JNM-GSX-500 (1H 500 MHz) or a JEOL JNM-EX-270 (1H 270 MHz) NMR spectrometer. Chemical shifts are reported in ppm downfield from internal Me₄Si. Optical rotations were measured with either a JASCO DIP-181 or a Horiba SEPA-300 polarimeter using a 1-dm sample tube. Elemental analyses and MS measurements were performed by Mr. Y. Itatani and his associates at Kanazawa University. The following abbreviations are used: d=doublet, dd=doublet-of-doublets, ddd=doublet-of-dd's, dddd=doubletof-ddd's, m=multiplet, s=singlet, t=triplet.

N-[(4-Methoxyphenyl)acetyl]-3,5-dimethoxy-2-[[(4-methoxyphenyl)methyl]thio]-L-phenylalanine Methyl Ester (8) A mixture of a solution of 3,5-dimethoxy-2-[[(4-methoxyphenyl)methyl]thio]-L-phenylalanine methyl ester $(7)^{6}$ (666 mg, 1.7 mmol) in benzene (12 ml) and a solution of Na₂CO₃ (180 mg, 1.7 mmol) in H_2O (12 ml) was stirred under ice-cooling, and a solution of 4-methoxyphenylacetyl chloride (314 mg, 1.7 mmol) in benzene (3 ml) was added dropwise over 5 min. After the mixture had been stirred at -10 °C for 30 min, the benzene layer was separated from the aqueous layer, which was extracted with benzene. The combined benzene solutions were washed successively with 5% aqueous HCl, saturated aqueous NaHCO₃, and saturated aqueous NaCl, dried, and concentrated to leave 8 (902 mg, 98%) as a colorless solid. Recrystallization of the solid from AcOEt-hexane (1:1, v/v) gave an analytical sample as colorless minute needles, mp 120—121 °C; $[\alpha]_{D}^{20}$ +19.8° (*c*=0.50, CHCl₃); MS *m/z*: 539 (M⁺); IR $v_{\text{max}}^{\text{CHCl}_3}$ cm⁻¹: 3420 (NH), 1740 (ester CO), 1667 (amide CO); ¹H-NMR (CDCl₃) δ : 2.92 (1H, dd, J=13.5, 9 Hz) and 3.05 (1H, dd, J=13.5, 5.5 Hz) (ArCH₂CH), 3.40 (2H, s, ArCH₂CO), 3.67, 3.72, 3.75, 3.79, and 3.88 (3H each, s, five MeO's), 3.77 and 3.78 (1H each, d, J=12.5 Hz, ArCH₂S), 4.68 (1H, ddd, J=9, 8, 5.5 Hz, ArCH₂CH), 5.74 (1H, d, J=8 Hz, NH), 6.19 and 6.36 [1H each, d, J=2.5 Hz, C(4)-H and C(6)-H], 6.71 (2H, d, J=8.5 Hz), 6.81 (2H, d, J=9 Hz), 6.96 (2H, d, J=9 Hz), and 7.04 (2H, d, J=8.5 Hz) (two 4-MeOC₆H₄'s). Anal. Calcd for C₂₉H₃₃NO₇S: C, 64.55; H, 6.16; N, 2.60. Found: C, 64.44; H, 6.11; N, 2.55.

(1S,3S)-6,8-Dimethoxy-1-[(4-methoxyphenyl)methyl]-5-[[(4-methoxyphenyl)methyl]thio]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Methyl Ester (9) i) Via Bischler-Napieralski Cyclization Using Toluene as a Solvent: A stirred mixture of 8 (216 mg, 0.40 mmol), POCl₃ (307 mg, 2.0 mmol), and toluene (4 ml) was heated at 80 °C for 7 h. After cooling, the solvent and excess POCl3 were distilled off in vacuo, and the residue was partitioned between CHCl3 and H2O. The CHCl3 extracts were washed with saturated aqueous NaCl, dried, and concentrated to leave a pale brown glass. The glass was dissolved in MeOH (12 ml), and the solution was cooled to -78 °C. NaBH₄ (30 mg, 0.8 mmol) was then added in small portions, and the mixture was stirred at -78 °C for 1 h. After addition of acetone (0.3 ml), the reaction mixture was brought to room temperature and concentrated in vacuo. The residual colorless solid was partitioned between CHCl₃ and H₂O. The CHCl₂ extracts were washed with saturated aqueous NaCl, dried, and concentrated to leave a reddish oil. Purification of the oil by flash chromatography [hexane-AcOEt (3:2, v/v)] furnished 9 (173 mg, 83%) as a colorless solid. The enantiomeric purity of this solid was determined to be 85% ee.8) Recrystallization from MeOH afforded an analytical sample as colorless needles, mp 135—136 °C; $[\alpha]_D^{20}$ –225° (*c*=0.25, CHCl₃); MS *m/z*: 522 (M⁺-1); IR $v_{\text{max}}^{\text{Nujol}}$ cm⁻¹: 3375 (NH), 1725 (ester CO); ¹H-NMR $(CDCl_3)$ δ : 2.07 [1H, dd, J=16, 11 Hz, C(4)-H_B], 2.71 (1H, dd, J=13.5, 7.5 Hz) and 3.21 (1H, dd, J=13.5, 3.5 Hz) [C(1)-CH₂], 3.10 [1H, dd, J=11, 3 Hz, C(3)-H], 3.20 [1H, dd, J=16, 3 Hz, C(4)-H_a], 3.70, 3.74, 3.76, 3.91, and 3.92 (3H each, s, five MeO's), 3.73 and 3.79 (1H each, d, J=12.5 Hz, ArCH₂S), 4.45 [1H, dd, J=7.5, 3.5 Hz, C(1)-H], 6.42 [1H, s, C(7)-H], 6.70, 6.78, 6.92, and 7.01 (2H each, d, J=9 Hz, two 4-MeOC₆H₄'s). Anal. Calcd for C₂₀H₂₂NO₆S: C, 66.52; H, 6.35; N, 2.67. Found: C, 66.37; H, 6.35; N, 2.80. The enantiomeric purity of this analytical sample was >98% ee.⁸⁾

ii) *Via* Bischler–Napieralski Cyclization Using CH₃CN as a Solvent: A stirred mixture of **8** (54 mg, 0.10 mmol), POCl₃ (30 mg, 0.20 mmol), and CH₃CN (0.5 ml) was heated at 60 °C for 10 h. Work-up of the reaction mixture and subsequent reduction with NaBH₄ (7.6 mg, 0.2 mmol) were carried out in a manner similar to method-(i), giving **9** (41 mg, 78%) as a colorless solid after purification by preparative TLC [AcOEt–hexane (1:1, v/v)]. The enantiomeric purity of this solid was found to be 96% ee.⁸⁾

(S)-N-[2-[3,5-Dimethoxy-2-[[(4-methoxyphenyl)methyl]thio]phenyl]-1-(hydroxymethyl)ethyl]-4-methoxybenzeneacetamide (11) A stirred solution of 8 (108 mg, 0.20 mmol) in THF (4 ml) was cooled to 0 °C, and LiBH₄ (26 mg, 1.2 mmol) was added in portions. After stirring at room temperature for 1.5 h, the reaction mixture was cooled in an ice bath, acidified with 10% aqueous HCl, and concentrated in vacuo. The residue was partitioned between CHCl₂ and saturated aqueous NaHCO₂. The CHCl₂ extracts were washed with saturated aqueous NaCl, dried, and concentrated. Purification of the residual solid by flash chromatography (AcOEt) yielded 11 (101 mg, 99%) as a colorless solid. Recrystallization from MeOH furnished an analytical sample as colorless needles, mp 134.5—135 °C; $[\alpha]_D^{16}$ –4.2° (*c*=0.54, CHCl₃); MS *m/z*: 511 (M⁺); IR v_{max}^{nax} cm⁻¹: 3390, 3320 (NH and OH), 1636 (amide CO); ¹H-NMR (CDCl₃) δ : 2.68 and 2.81 (1H each, dd, *J*=13.5, 7.5 Hz, ArCH₂CH), 3.17 (1H, t, J=6.5 Hz, OH), 3.39-3.50 (2H, m, CH₂OH), 3.42 (2H, s, ArCH₂CO), 3.749, 3.751, 3.80, and 3.87 (3H each, s, four MeO's), 3.77 and 3.83 (1H each, d, J=12.5 Hz, ArCH₂S), 3.87 (1H, m, ArCH₂CH), 5.71 (1H, d, J=7.5 Hz, NH), 6.31 and 6.36 [1H each, d, J=2.5 Hz, C(4)-H and C(6)-H], 6.71, 6.83, 6.96, and 7.05 (2H each, d, J=8.5 Hz, two 4-MeOC₆H₄'s). Anal. Calcd for C₂₈H₃₃NO₆S: C, 65.73; H, 6.50; N, 2.74. Found: C, 65.74; H, 6.62; N, 2.77.

(S)-N-[2-(Acetyloxy)-1-[[3,5-dimethoxy-2-[[(4-methoxyphenyl)methyl]thio]phenyl]methyl]ethyl]-4-methoxybenzeneacetamide (12) A mixture of 11 (537 mg, 1.05 mmol) and Ac₂O (0.4 ml, 4.2 mmol) in pyridine (3 ml) was stirred at room temperature for 1.5 h. The reaction mixture was concentrated in vacuo, and the residue was partitioned between CHCl₃ and H₂O. The CHCl₃ extracts were washed successively with 5% aqueous HCl, saturated aqueous NaHCO3, and saturated aqueous NaCl, dried over anhydrous MgSO₄, and concentrated to leave a slightly yellowish solid. Recrystallization from AcOEt-hexane (1:1, v/v) gave a first crop (450 mg) of 12. Concentration of the mother liquor and recrystallization of the residue afforded a second crop (90 mg) of 12. Total yield of 12 was 540 mg (93%). Further recrystallization from the same solvent system produced an analytical sample as colorless fluffy needles, mp 116–117.5 °C; $[\alpha]_{\rm D}^{27}$ –10.2° $(c=0.52, \text{ CHCl}_3)$; MS m/z: 553 (M⁺); IR $v_{\text{max}}^{\text{Nujol}}$ cm⁻¹: 3275 (NH), 1732 (ester CO), 1653 (amide CO); ¹H-NMR (CDCl₃) δ: 1.99 (3H, s, CH₃CO), 2.71 (1H, dd, J=14, 6.5 Hz) and 2.76 (1H, dd, J=14, 9 Hz) (ArCH₂CH), 3.36 (2H, s, ArCH₂CO), 3.73, 3.75, 3.80, and 3.89 (3H each, s, four MeO's), 3.78 and 3.83 (1H each, d, J=12.5 Hz, ArCH₂S), 3.92 (1H, dd, J=11, 4.5 Hz) and 3.94 (1H, dd, J=11, 5.5 Hz) (CH₂OAc), 4.31 (1H, m, ArCH₂CH), 5.37 (1H, d, J=8.5 Hz, NH), 6.25 and 6.36 [1H each, d, J=2.5 Hz, C(4)-H and C(6)-H], 6.71, 6.82, 6.97, and 7.02 (2H each, d, J=8.5 Hz, two 4-MeOC₆H₄'s). *Anal.* Calcd for C₃₀H₃₅NO₇S: C, 65.08; H, 6.37; N, 2.53. Found: C, 64.91; H, 6.46; N, 2.34.

(1S,3S)-3-Acetyloxymethyl-6,8-dimethoxy-1-[(4-methoxyphenyl)methyl]-5-[[(4-methoxyphenyl)methyl]thio]-1,2,3,4-tetrahydroisoquinoline (13) A stirred mixture of 12 (332 mg, 0.60 mmol) and POCl₃ (460 mg, 3.0 mmol) in toluene (8 ml) was heated under reflux for 1.5 h. Work-up of the reaction mixture followed by reduction with NaBH₄ (45 mg, 1.2 mmol) in MeOH (18 ml) at -78 °C for 1 h was effected as described above for 9, furnishing a crude yellow oil. Purification of the oil by flash chromatography [AcOEt-hexane (1:1, v/v)] gave 13 (283 mg, 88%) as a slightly yellowish oil, $[\alpha]_{D}^{27}$ -205° (c=0.43, CHCl₃); MS m/z: 536 (M⁺-1); IR $v_{max}^{CHCl_3}$ 1732 cm⁻¹ (ester CO); ¹H-NMR (CDCl₃) δ : 1.75 [1H, dd, J=16, 11 Hz, C(4)-H_β], 2.02 (3H, s, CH₃CO), 2.52 [1H, m, C(3)-H], 2.74 (1H, dd, J=13.5, 7 Hz) and 3.13 (1H, dd, J=13.5, 3.5 Hz) [C(1)-CH2], 2.79 [1H, dd, J=16, 2.5 Hz, C(4)-H_a], 3.71 and 3.77 (1H each, d, J=12.5 Hz, ArCH₂S), 3.73, 3.75, 3.91, and 3.93 (3H each, s, four MeO's), 3.84 (1H, dd, J=11, 6 Hz) and 3.98 (1H, dd, J=11, 4 Hz) (CH₂OAc), 4.44 [1H, dd, J=7, 3.5 Hz, C(1)-H], 6.42 [1H, s, C(7)-H], 6.69, 6.75, 6.90, and 6.95 (2H each, d, J=8.5 Hz, two 4- $MeOC_6\underline{H}_4\mbox{'s});$ high-resolution MS calcd for $C_{30}H_{35}NO_6S$: 537.2185, found: 537.2182

(1S,3S)-6,8-Dimethoxy-3-hydroxymethyl-1-[(4-methoxyphenyl)methyl]-5-[[(4-methoxyphenyl)methyl]thio]-1,2,3,4-tetrahydroisoquinoline (10) i) From 9: A stirred suspension of LiAlH₄ (42 mg, 1.1 mmol) in THF (8 ml) was cooled to 0 °C, and a solution of 9 (388 mg, 0.74 mmol) in THF (6 ml) was added dropwise over 10 min. After the mixture had been stirred at room temperature for 1.5 h, THF-H₂O (4:1, v/v) (2 ml) was added under ice-cooling. Stirring was continued at room temperature for 20 min, and the insoluble material was filtered off. The filtrate was concentrated in vacuo to leave a pale yellow solid, which was taken up in CHCl₃. The CHCl₃ solution was washed with saturated aqueous NaCl, dried, and concentrated. Recrystallization of the residual solid from EtOH afforded 10 (309 mg, 84%) as colorless minute needles. Further recrystallization from EtOH provided an analytical sample, mp 171.5—174.5 °C; $[\alpha]_{\rm D}^{17}$ -227° (c=0.25, CHCl₃); MS m/z: 495 (M⁺); IR v_{max}^{Nujol} cm⁻¹: 3305, 3165 (NH and OH); ¹H-NMR (CDCl₃) δ : 1.82 [1H, dd, J=16, 11.5 Hz, C(4)-H₈], 2.45 [1H, m, C(3)-H], 2.67 (1H, dd, J=13.5, 7.5 Hz) and 3.10 (1H, dd, J=13.5, 4 Hz) [C(1)-CH₂], 2.82 [1H, dd, J=16, 2.5 Hz, C(4)-H_a], 3.27 (1H, dd, J=10.5, 6 Hz) and 3.49 (1H, dd, J=10.5, 4Hz) (CH2OH), 3.72 and 3.77 (1H each, d, J=12.5 Hz, ArCH₂S), 3.74, 3.76, 3.89, and 3.93 (3H each, s, four MeO's), 4.44 [1H, dd, J=7.5, 4 Hz, C(1)-H], 6.41 [1H, s, C(7)-H], 6.69, 6.77, 6.91, and 6.97 (2H each, d, J=8.5 Hz, two 4-MeOC6H4's). Anal. Calcd for C₂₈H₃₃NO₅S: C, 67.85; H, 6.71; N, 2.83. Found: C, 68.05; H, 6.93; N, 2.83.

ii) From 13: A solution of 13 (108 mg, 0.20 mmol) in MeOH (3 ml) was cooled to 0 °C, and a solution of K_2CO_3 (69 mg, 0.50 mmol) in H_2O (0.3 ml) was added. After stirring at room temperature for 1 h, the reaction mixture was partitioned between CHCl₃ and H_2O . The CHCl₃ extracts were washed with saturated aqueous NaCl, dried over anhydrous MgSO₄, and concentrated to leave a colorless solid. Recrystallization of the solid from EtOH yielded 10 (86 mg, 86%) as colorless fluffy needles, mp 171–173 °C. This sample was identical (by comparison of the IR spectrum and TLC behavior) with the one obtained by method-(i).

(55,10a.S)-6,8-Dimethoxy-5-[(4-methoxyphenyl)methyl]-9-[[(4-methoxyphenyl)methyl]thio]-1,5,10,10a-tetrahydroxazolo[3,4-b]isoquinolin-3(3H)-one (14) A suspension of 10 (464 mg, 0.94 mmol) in absolute EtOH (17 ml) was stirred at room temperature, and a 1.0 m solution (1.9 ml, 1.9 mmol) of NaOEt in absolute EtOH and diethyl carbonate (1.2 ml, 9.9 mmol) were added. The resulting mixture was then heated under reflux for 6 h. After addition of AcOH (1.5 ml), the reaction mixture was concentrated *in vacuo*, and the residue was partitioned between CHCl₃ and 10% aqueous NaHCO₃ and saturated aqueous NaCl, dried, and concentrated. Purification of the residual oil by flash chromatography [hexane–AcOEt (1 : 1, v/v)] furnished 14 (446 mg, 91%) as a colorless foam, $[\alpha]_{D}^{18} -331^{\circ}$ (*c*=0.25, CHCl₃); MS *m/z*: 520 (M⁺-1); IR $v_{max}^{CHCl_3}$ 1742 cm⁻¹ (oxazolidinone CO); ¹H-NMR (Table 1).

(55,10aS)-6,8-Dimethoxy-9-mercapto-5-[(4-methoxyphenyl)methyl]-1,5,10,10a-tetrahydroxazolo[3,4-*b*]isoquinolin-3(3*H*)-one (15) A mixture of 14 (436 mg, 0.84 mmol), anisole (452 mg, 4.2 mmol), mercuric trifluoroacetate (544 mg, 1.3 mmol), and absolute EtOH (17 ml) was stirred at room temperature for 14.5 h. After addition of NaBH₄ (127 mg, 3.4 mmol) under ice-cooling, the reaction mixture was stirred at 0 °C for 15 min and then acidified with 10% aqueous HCl. The insoluble material was removed by filtration, and the filtrate was concentrated *in vacuo*. The residue was partitioned between CHCl₃ and H₂O. The CHCl₃ extracts were washed with saturated aqueous NaCl, dried, and concentrated to leave a yellow oil. Purification of the oil by flash chromatography [hexane–AcOEt (1:1, v/v)] gave **15** (301 mg, 90%) as a colorless glass, $[\alpha]_D^{17} - 235^\circ$ (*c*=0.25, CHCl₃); MS *m/z*: 400 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 2590 (SH), 1742 (oxazolidinone CO); ¹H-NMR (Table 1).

(55,10aS)-6,8-Dimethoxy-9-[(5-formyl-1-methyl-1*H*-imidazol-4-yl)thio]-5-[(4-methoxyphenyl)methyl]-1,5,10,10a-tetrahydroxazolo[3,4-*b*]isoquinolin-3(3*H*)-one (16) A mixture of 15 (128 mg, 0.32 mmol) and an oil dispersion (14 mg) containing 60% NaH (0.35 mmol) in dry DMF (3 ml) was stirred at room temperature, and 4-bromo-1-methyl-1*H*-imidazole-5carbaldehyde (23)⁵⁾ (66 mg, 0.35 mmol) was added. The resulting mixture was heated at 100 °C in an atmosphere of N₂ for 3 h. After cooling, the reaction mixture was concentrated *in vacuo* to leave an orange oil, which was partitioned between CH₂Cl₂ and H₂O. The CH₂Cl₂ extracts were washed with saturated aqueous NaCl, dried, and concentrated. Purification of the residual yellow oil by flash chromatography [AcOEt=EtOH (20 : 1, v/v)] furnished 16 (134 mg, 82%) as a yellowish foam, $[\alpha]_D^{16} - 107^\circ$ (*c*=0.25, CHCl₃); MS *m/z*: 508 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 1741 (oxazolidinone CO), 1662 (CHO); ¹H-NMR (Table 1).

(5S,10aS)-6,8-Dimethoxy-9-[(5-hydroxymethyl-1-methyl-1H-imidazol-4-yl)thio]-5-[(4-methoxyphenyl)methyl]-1,5,10,10a-tetrahydroxazolo[3,4b]isoquinolin-3(3H)-one (17) A solution of 16 (248 mg, 0.49 mmol) in MeOH (5 ml) was stirred at room temperature, and NaBH₄ (20 mg, 0.53 mmol) was added in small portions. After the mixture had been stirred at room temperature for 1 h, acetone (2 ml) was added. The resulting mixture was concentrated in vacuo, and the residual solid was partitioned between CH₂Cl₂ and H₂O. The CH₂Cl₂ extracts were washed with saturated aqueous NaCl, dried, and concentrated to leave a colorless solid. Recrystallization from MeOH gave a first crop (180 mg) of 17. A second crop (24 mg) of 17 was obtained by concentration of the mother liquor and subsequent purification of the residue by flash chromatography [AcOEt-EtOH (5:1, v/v)]. Total yield of 17 was 204 mg (82%). Further recrystallization from MeOH provided an analytical sample as colorless prisms, mp 250.5–251.5 °C; $[\alpha]_D^{20}$ -87.5° (c=0.25, CHCl₃); MS m/z: 511 (M⁺); IR v_{max}^{Nujol} cm⁻¹: 3180 (OH), 1753 (oxazolidinone CO); ¹H-NMR (Table 1). Anal. Calcd for C₂₆H₂₉N₃O₆S: C, 61.04; H, 5.71; N, 8.21. Found: C, 60.87; H, 5.74; N, 8.19

X-Ray Structure Determination of 17 For X-ray diffraction analysis, colorless transparent prisms of 17 were grown from MeOH. A crystal measuring $0.20 \times 0.10 \times 0.10$ mm was selected from among them and used for all data collection. Unit cell constants and intensity data were obtained with a Rigaku AFC-5R four-circle diffractometer controlled by the MSC/ AFC program package, using graphite-monochromated Mo K_{α} radiation $(\lambda = 0.71069 \text{ Å})$, in the $2\theta - \omega$ scan mode. Crystal data of 17: $C_{26}H_{29}N_3O_6S$; M=511.59; orthorhombic; space group $P2_12_12_1$; Z=4; a=11.703(6) Å; b=18.496(5) Å; c=11.653(2) Å; V=2522(1) Å³; $D_{calcd}=1.347$ g/cm³. Reflections (1307) with intensity above the $3\sigma(I)$ level were used for the structure determination. The structure was solved by a direct method using Mithril¹⁷) and refined by the full-matrix least-squares method with anisotropic temperature factors for non-hydrogen atoms. All hydrogen atoms were clearly located on the difference Fourier maps and refined with isotropic temperature factors. The final *R* value was $0.036 (R_w=0.036)$.

(55,10aS)-9-[[5-[(2S-trans)-2,5-Dihydro-3,6-dimethoxy-2-(1-methylethyl)pyrazin-5-yl]methyl-1-methyl-1*H*-imidazol-4-yl]thio]-6,8dimethoxy-5-[(4-methoxyphenyl)methyl]-1,5,10,10a-tetrahydroxazolo[3,4-b]isoquinolin-3(3*H*)-one (21) and (55,10aS)-9-[[5-[(2S-cis)-2,5-Dihydro-3,6-dimethoxy-2-(1-methylethyl)pyrazin-5-yl]methyl-1-methyl-1*H*-imidazol-4-yl]thio]-6,8-dimethoxy-5-[(4-methoxyphenyl)methyl]-1,5,10,10a-tetrahydroxazolo[3,4-b]isoquinolin-3(3*H*)-one (22) A mixture of 17 (560 mg, 1.1 mmol) and SOCl₂ (3.3 ml) was stirred at room temperature for 1 h. The reaction mixture was concentrated *in vacuo*, and the residual oil was co-evaporated with three 10-ml portions of THF to leave 18 as a pale yellow glass. This sample was directly used in the next step without further purification.

In a separate flask, a stirred solution of diisopropylamine (0.46 ml, 3.3 mmol) in THF (4 ml) was cooled to -78 °C in an atmosphere of Ar, and a 1.48 M solution (2.25 ml, 3.3 mmol) of BuLi in hexane was added dropwise. After the mixture had been stirred for 40 min, a solution of (2*S*)-(+)-2,5-di-hydro-3,6-dimethoxy-2-isopropylpyrazine¹⁸) (607 mg, 3.3 mmol) in THF (2 ml) was added dropwise. Stirring was then continued for 20 min, and a solution of the above chloride **18** in THF (5 ml) was added dropwise over 3 min. The resulting mixture was stirred first at -78 °C for 2 h and then at -50 °C for 20 h. The reaction was quenched by adding saturated aqueous NH₄Cl (5

ml) at -50 °C, and the mixture was allowed to warm to room temperature. The THF was removed in vacuo, and the residue was partitioned between CH₂Cl₂ and H₂O. The CH₂Cl₂ extracts were washed with saturated aqueous NaCl, dried over anhydrous MgSO4, and concentrated to leave a pale brown oil, which was then subjected to flash chromatography [AcOEt-acetone (1:1, v/v)]. Earlier fractions furnished 21 (410 mg, 55%) as a colorless glass, $[\alpha]_{D}^{19} - 32.2^{\circ}$ (c=0.53, CHCl₃); MS m/z: 676 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 1742 (oxazolidinone CO), 1693 (C=N); ¹H-NMR (CDCl₃) δ : 0.69 and 0.97 $(3H \text{ each, } d, J=7 \text{ Hz}, CHMe_2), 0.85 [1H, dd, J=15, 11 \text{ Hz}, C(10)-H_{\beta}], 2.13$ (1H, m, C<u>H</u>Me₂), 2.72 (1H, dd, J=13.5, 2 Hz) and 3.61 (1H, dd, J=13.5, 5 Hz) $[C(5)-CH_2]$, 2.76 (1H, dd, J=14.5, 9.5 Hz) and 3.66 (1H, dd, J=14.5, 4.5 Hz) [C(5")-CH₂], 3.61, 3.63, 3.74, 3.78, 3.86, and 3.88 (3H each, s, NMe and five MeO's), 3.64 (1H, dd, J=11, 7.5 Hz) and 4.35 (1H, dd, J=7.5 Hz each) [C(1)-H's], 3.73 [1H, m, C(10a)-H], 3.78 [1H, dd, J=4 Hz each, C(2")-H], 3.80 [1H, dd, J=15, 3.5 Hz, C(10)-H_a], 4.06 [1H, ddd, J=9.5, 4.5, 4 Hz, C(5")-H], 5.30 [1H, dd, J=5, 2 Hz, C(5)-H], 6.37 [2H, d, J=8.5 Hz, C(3')-H and C(5')-H], 6.40 [1H, s, C(7)-H], 6.48 [2H, d, J=8.5 Hz, C(2')-H and C(6')-H], 7.24 (1H, s, imidazole ring proton).¹⁹⁾

Later fractions in the above chromatography gave **22** (230 mg, 31%) as a colorless glass, $[\alpha]_D^{19} - 8.7^{\circ}$ (c=0.46, CHCl₃); MS m/z: 676 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 1742 (oxazolidinone CO), 1693 (C=N); ¹H-NMR (CDCl₃) δ : 0.73 and 1.07 (3H each, d, J=7 Hz, CH<u>Me</u>₂), 0.87 [1H, dd, J=15.5, 12 Hz, C(10)-H_{β}], 2.17 (1H, m, C<u>H</u>Me₂), 2.79 (1H, dd, J=13.5, 2.5 Hz) and 3.61 (1H, dd, J=14.5, 4.5 Hz) [C(5)-CH₂], 2.96 (1H, dd, J=14.5, 9.5 Hz) and 3.30 (1H, dd, J=14.5, 4.5 Hz) [C(5)'-CH₂], 3.58 (3H), 3.63 (3H), 3.75 (6H), and 3.86 (6H) (s each, NMe and five MeO's), 3.63 (1H, dd, J=11, 8 Hz) and 4.35 (1H, dd, J=8 Hz each) [C(1)-H's], 3.72—3.80 [2H, m, C(10)-H_{α} and C(10a)-H], 3.93 [1H, dd, J=4.5 Hz each, C(2")-H], 4.24 [1H, ddd, J=9.5, 4.5, 4.5 Hz, C(5')-H], 5.31 [1H, dd, J=5, 2.5 Hz, C(5)-H], 6.42 [1H, s, C(7)-H], 6.45 [2H, d, J=9 Hz, C(3')-H and C(5')-H], 6.51 [2H, d, J=9 Hz, C(2')-H and C(6')-H], 7.24 (1H, s, imidazole ring proton).¹⁹

(5S,10aS)-5-[[6,8-Dimethoxy-5-[(4-methoxyphenyl)methyl]-3(3H)-oxo-1,5,10,10a-tetrahydroxazolo[3,4-b]isoquinolin-9-yl]thio]-3-methyl-p-histidine Methyl Ester (5) A mixture of 21 (59 mg, 0.087 mmol) and 0.25 N aqueous HCl (3.5 ml) in MeOH (1.8 ml) was stirred at room temperature for 8.5 h. The reaction mixture was concentrated in vacuo to half the initial volume, made basic with 28% aqueous NH₃, and extracted with CH₂Cl₂. The CH2Cl2 extracts were washed with saturated aqueous NaCl, dried over anhydrous MgSO₄, and concentrated. Purification of the residual yellow oil by flash chromatography [CH₂Cl₂-EtOH (9:1, v/v)] gave 5 (36 mg, 71%) as a colorless glass; $[\alpha]_D^{22} = -87.8^{\circ}$ (c=0.25, CHCl₃); MS m/z: 581 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 3390 and 3320 (NH₂), 1740 (ester and oxazolidinone CO's); ¹H-NMR (CDCl₃) δ : 0.84 [1H, dd, J=15.5, 11.5 Hz, C(10')-H_g], 2.77 (1H, dd, J=13.5, 2 Hz) and 3.62 (1H, dd, J=13.5, 5 Hz) [C(5')-CH₂], 2.88 (1H, dd, J=14.5, 9.5 Hz) and 3.19 (1H, dd, J=14.5, 5.5 Hz) [C(4)-CH₂], 3.60, 3.74, 3.76, 3.89, and 3.91 (3H each, s, NMe and four MeO's), 3.65 (1H, dd, J=10.5, 7.5 Hz) and 4.36 (1H, dd, J=7.5 Hz each) [C(1')-H's], 3.70-3.78 [2H, m, C(10')-H_{α} and C(10'a)-H], 3.77 [1H, dd, J=9.5, 5.5 Hz, C(4)-CH₂C<u>H</u>], 5.30 [1H, dd, J=5, 2 Hz, C(5')-H], 6.42 [2H, d, J=9 Hz, C(3")-H and C(5")-H], 6.45 [1H, s, C(7')-H], 6.47 [2H, d, J=9 Hz, C(2")-H and C(6")-H], 7.25 [1H, s, C(2)-H].²⁰⁾

(5S,10aS)-5-[[6,8-Dimethoxy-5-[(4-methoxyphenyl)methyl]-3(3H)-oxo-1,5,10,10a-tetrahydroxazolo[3,4-b]isoquinolin-9-yl]thio]-3-methyl-L-histidine Methyl Ester (6) A mixture of 22 (230 mg, 0.34 mmol) and 0.25 N aqueous HCl (13.5 ml) in MeOH (3 ml) was stirred at room temperature for 26 h. The reaction mixture was worked up as described above for 5, giving 6 (149 mg, 75%) as a colorless glass; $[\alpha]_{D}^{20}$ -67.7° (*c*=0.25, CHCl₃); MS *m/z*: 581 (M⁺-1); IR $v_{max}^{CHCl_3}$ cm⁻¹: 3390 and 3320 (NH₂), 1740 (ester and oxazolidinone CO's); ¹H-NMR (CDCl₃) δ : 0.87 [1H, dd, J=15.5, 11.5 Hz, C(10')-H_β], 2.77 (1H, dd, J=13.5, 2.5 Hz) and 3.62 (1H, dd, J=13.5, 4.5 Hz) $[C(5')-CH_2]$, 3.01 (1H, dd, J=14.5, 9 Hz) and 3.09 (1H, dd, J=14.5, 5.5 Hz) [C(4)-CH₂], 3.60, 3.74, 3.77, 3.89, and 3.91 (3H each, s, NMe and four MeO's), 3.66 (1H, dd, J=11, 7.5 Hz) and 4.36 (1H, dd, J=7.5 Hz each) [C(1')-H's], 3.73 [1H, dd, J=15.5, 3 Hz, $C(10')-H_{\alpha}]$, 3.74 [1H, m, C(10'a)-H], 3.85 [1H, dd, J=9, 5.5 Hz, C(4)-CH₂CH], 5.31 [1H, dd, J=4.5, 2.5 Hz, C(5')-H], 6.42 [2H, d, J=9 Hz, C(3")-H and C(5")-H], 6.44 [1H, s, C(7')-H], 6.46 [2H, d, J=9 Hz, C(2")-H and C(6")-H], 7.26 [1H, s, C(2)-H].²⁰⁾

(5*S*,10a*S*)-6,8-Dimethoxy-5-[(4-methoxyphenyl)methyl]-1,5,10,10atetrahydroxazolo[3,4-*b*]isoquinolin-3(3*H*)-one (27) and 3-Methyl-p-histidine (28) A stirred mixture of 5 (36 mg, 0.062 mmol), MeOH (4 ml), H₂O (1 ml), and Raney Ni²¹⁾ (0.5 ml) was heated under reflux for 1 h. The catalyst was removed by filtration and washed with MeOH. The filtrate and the washings were combined and concentrated *in vacuo*. Purification of the residue by flash chromatography [CH₂Cl₂–MeOH (20: 1, v/v)] furnished 27 (19 mg, 83%) as a colorless glass; $[\alpha]_{\rm D}^{17}$ -267° (c=0.28, CHCl₃); MS m/z: 368 (M⁺-1); IR $v_{max}^{CHCl_3}$ 1742 cm⁻¹ (oxazolidinone CO); ¹H-NMR (CDCl₃) δ: 1.07 [1H, dd, J=14, 11.5 Hz, C(10)-H_β], 2.27 [1H, dd, J=14, 3 Hz, $C(10)-H_{\alpha}$], 2.85 (1H, dd, J=13.5, 2Hz) and 3.66 (1H, dd, J=13.5, 5Hz) $[C(5)-CH_2]$, 3.58 (1H, dd, J=11, 7.5 Hz) and 4.30 (1H, dd, J=7.5 Hz each) [C(1)-H's], 3.77 [1H, m, C(10a)-H], 3.74, 3.79, and 3.87 (3H each, s, three MeO's), 5.30 [1H, dd, J=5, 2 Hz, C(5)-H], 6.04 [1H, d, J=2 Hz, C(9)-H], 6.43 [1H, d, *J*=2 Hz, C(7)-H], 6.52 [2H, d, *J*=8.5 Hz, C(3')-H and C(5')-H], 6.64 [2H, d, J=8.5 Hz, C(2')-H and C(6')-H].¹⁹ The catalyst, obtained by filtration of the original reaction mixture described above, was added to cold 6 N aqueous HCl (50 ml), and the mixture was stirred at room temperature for 4 h. The insoluble material was filtered off, and the filtrate was concentrated in vacuo to leave a greenish glass, which was dissolved in H₂O. The aqueous solution was applied to a column of Dowex 50W-X2 (H⁺ form), and the column was eluted with 1 N aqueous HCl. After elution of Ni²⁺ fractions showing a positive reaction to the ninhydrin test were combined and concentrated in vacuo. The residue was then dissolved in H2O and applied to a column of Dowex 50W-X8 (H⁺ form). The column was first eluted with H₂O until the eluate became neutral, and then with 2% aqueous NH₃. The ammoniacal eluates were combined and concentrated in vacuo to leave a colorless solid. The solid was triturated with H₂O, and the insoluble material was removed by filtration. The filtrate was concentrated in vacuo to dryness to leave $28 \cdot H_2O$ (5.3 mg, 46%) as a colorless solid, $[\alpha]_D^{21} - 11.3^\circ$ (c= 0.31, 0.1 N aqueous HCl). The ¹H-NMR spectrum (D₂O) and TLC mobility of this sample were identical with those of a commercial sample of 3methyl-L-histidine monohydrate (*ent*-28 · H₂O) $\left[\left[\alpha\right]_{D}^{23} + 10.8^{\circ}\right]$ (*c*=0.30, 0.1 N aqueous HCl)].

Acknowledgment We are grateful to Dr. Shinzo Hosoi (Kanazawa University) for his full assistance in X-ray analysis. This work was supported by a Grant-in-Aid for Scientific Research (C) (No. 06672097) from the Ministry of Education, Science, Sports and Culture, Japan.

References and Notes

- Pathirana C., Andersen R. J., J. Am. Chem. Soc., 108, 8288–8289 (1986).
- Elliott J. K., Ross D. M., Pathirana C., Miao S., Andersen R. J., Singer P., Kokke W. C. M. C., Ayer W. A., *Biol. Bull.*, **176**, 73–78 (1989).
- Burgoyne D. L., Miao S., Pathirana C., Andersen R. J., Ayer W. A., Singer P. P., Kokke W. C. M. C., Ross D. M., *Can. J. Chem.*, 69, 20– 27 (1991).
- Ohba M., Nishimura Y., Imasho M., Fujii T., Kubanek J., Andersen R. J., *Tetrahedron Lett.*, 39, 5999–6002 (1998).
- a) Ohba M., Mukaihira T., Fujii T., *Heterocycles*, 33, 21–26 (1992);
 b) Idem, Chem. Pharm. Bull., 42, 1784–1790 (1994).
- 6) Ohba M., Imasho M., Fujii T., Heterocycles, 42, 219-228 (1996).
- 7) Ishida A., Nakamura T., Irie K., Oh-ishi T., Chem. Pharm. Bull., 33,

3237-3249 (1985).

- By means of ¹H-NMR spectroscopy employing the chiral shift reagent tris[3-(heptafluoropropylhydroxymethylene)-(+)-camphorato]europium(III) [Eu(hfc)₃] in CDCl₃.
- Kametani T., Takagi N., Kanaya N., Honda T., *Heterocycles*, **19**, 535– 537 (1982).
- 10) a) Kametani T., Takagi N., Toyota M., Honda T., Fukumoto K., *Heterocycles*, 16, 591—594 (1981); b) *Idem, J. Chem. Soc.*, *Perkin Trans. 1*, 1981, 2830—2834.
- a) Akabori S., Sakakibara S., Shimonishi Y., Nobuhara Y., Bull. Chem. Soc. Jpn., 37, 433—434 (1964); b) Sakakibara S., Shimonishi Y., ibid., 38, 1412—1413 (1965); c) Yajima H., Fujii N., Ogawa H., Kawatani H., J. Chem. Soc., Chem. Commun., 1974, 107—108; d) Fujii N., Otaka A., Ikemura O., Akaji K., Funakoshi S., Hayashi Y., Kuroda Y., Yajima H., ibid., 1987, 274—275; e) Fujii N., Otaka A., Funakoshi S., Bessho K., Watanabe T., Akaji K., Yajima H., Chem. Pharm. Bull., 35, 2339—2347 (1987); f) Fujii N., Otaka A., Ikemura O., Hatano M., Okamachi A., Funakoshi S., Sakurai M., Shioiri T., Yajima H., ibid., 35, 3447—3452 (1987); g) Fujii N., Otaka A., Sugiyama N., Hatano M., Yajima H., ibid., 35, 3880—3883 (1987); h) Fujii N., Otaka A., Watanabe T., Okamachi A., Tamamura H., Yajima H., Inagaki Y., Nomizu M., Asano K., J. Chem. Soc., Chem. Commu., 1989, 283—284.
- a) Fujino M., Nishimura O., J. Chem. Soc., Chem. Commun., 1976, 998; b) Nishimura O., Kitada C., Fujino M., Chem. Pharm. Bull., 26, 1576—1585 (1978); c) Holler T. P., Ruan F., Spaltenstein A., Hopkins P. B., J. Org. Chem., 54, 4570—4575 (1989).
- a) Schöllkopf U., Top. Curr. Chem., 109, 65–84 (1983); b) Idem, Pure Appl. Chem., 55, 1799–1806 (1983).
- 14) The diastereoisomeric ratio was determined by ¹H-NMR spectral analysis.
- 15) The stereochemical assignments for the dihydropyrazine rings of **19** and **20** were made by comparison of the C(2")-proton signals of **19** (δ 3.80) and **20** (δ 3.93) as described in the text for those of **21** and **22**.
- 16) Still W. C., Kahn M., Mitra A., J. Org. Chem., 43, 2923-2925 (1978).
- Gilmore G., "Mithril: a Computer Program for the Automatic Solution of Crystal Structures from X-Ray Data," University of Glasgow, Scotland, 1983.
- A Merck–Schuchardt product was purchased through Kanto Chemical Co. (Japan) and purified by vacuum distillation before use.
- 19) For convenience, each position in the 4-methoxyphenyl moiety is indicated by a primed number and that of the dihydropyrazine ring by a doubly primed number in compounds 21 and 22.
- 20) For convenience, each skeletal atom in the oxazolo[3,4-b]isoquinoline moiety is indicated by a primed number and each aromatic carbon in the 4-methoxyphenyl moiety by a doubly primed number.
- 21) Fujii T., Yoshifuji S., Tetrahedron, 26, 5953-5958 (1970).